RxDoctor Payments Data

Mohammed Alnijoumi, MD

Pulmonary Disease · Detroit, MINPI 1699938449

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (54.6%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 75.1% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $5,533 and has fallen 98.5% since, to $80 in 2025.

$7,323in general payments, 2019–2025

Across 28 payments — averaging $261.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$5K
  • Pulmonx Corporation$1K
  • Veran Medical Technologies, Inc.$352
  • GSK$53
  • Olympus America Inc.$45
  • Ambu Inc.$34
  • plus $36 from 2 others
$27,876in research payments, 2019–2025

Across 2 payments — averaging $13,938 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biotest AG$28K

What the payments were for

  • Travel & lodging$2,33032%
  • Food & beverage$99314%
  • Education$4,00055%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,323 in reported general payments places this provider in the 75th percentile of 463 pulmonary disease providers in Michigan.

See all pulmonary disease providers in Michigan

Medicare billing

Part B allowed, 2024
$32,900
Medicare patients
139
Services billed
326

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$13,930
Incruse ElliptaUmeclidinium Bromide11$5,718
SymbicortBudesonide/Formoterol Fumarate16$4,973
Advair HfaFluticasone Propion/Salmeterol11$3,066
Albuterol Sulfate HfaAlbuterol Sulfate15$801

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Incruse Ellipta$53$19,64728 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 463 pulmonary disease providers in Michigan.

Other pulmonary disease in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →